Peptide side effects
Every medication that does something can do something unwanted. These articles catalogue peptide side effects and those reported for GLP-1 medications — nausea, injection-site reactions, and the rarer things worth knowing about — plus what researchers report about how long effects last and what tends to help.
Honest side-effect information is a feature, not a liability: it's how you and your provider decide together whether a treatment fits. Where an effect has its own article — nausea, hair shedding, fatigue — you'll find the detail there.
56 articles on this topic
-
Does Semaglutide Cause Cancer? What Studies Show
Human studies have not established that semaglutide causes cancer. The thyroid warning remains, and lower cancer rates in some studies are not proof of prevention.
-
STEP 1 Trial Results: What the 14.9% Average Means
The 68-week semaglutide study found 14.9% average weight loss versus 2.4% with placebo. The details show who was studied, who stopped treatment and what happened later.
-
Tirzepatide and Kidney Disease: Risks and Evidence
Kidney disease does not automatically rule out tirzepatide. The key questions are dehydration risk, recent kidney tests and what the newer studies actually measured.
-
SURMOUNT-1 Results: What the Trial Actually Found
SURMOUNT-1 followed 2,539 adults without diabetes for 72 weeks. Average weight change ranged from -15.0% to -20.9% with tirzepatide, compared with -3.1% with placebo.
-
Zepbound Prescribing Information, Explained
The current label is revised August 2026. It covers two uses, a weekly dose ladder, two absolute contraindications, the boxed thyroid warning, common stomach side effects, pregnancy, and four delivery formats.
-
Semaglutide Meal Plan: A Simple Day Structure
A useful plan is flexible: smaller meals, protein early, fiber at a tolerable pace, and fluids across the day. This sample day uses portion ranges rather than a calorie rule.
-
Compounded Semaglutide Side Effects: What Changes?
Most compounded semaglutide side effects come from semaglutide itself. Compounding can add separate risks involving concentration, added ingredients, ingredient form, sterility, and labeling.
-
SS-31 Side Effects: What the Trials Found
SS-31 most often caused redness, itching, pain, or swelling where it was injected. Most reactions in trials were mild to moderate, but the label also warns about allergic reactions that can become serious.
-
Is CJC-1295 Ipamorelin Safe? What We Know
Short human studies offer limited reassurance, but the blend itself has not been tested in a published trial and its long-term safety is unknown. A careful answer has to include both facts.
-
Tirzepatide Meal Plan: Small Meals, Protein First
A useful tirzepatide meal plan is smaller and steadier: protein first, produce and fiber as tolerated, and fluids between meals. It should bend around appetite and side effects, not force a calorie target.
-
Where to Inject MOTS-c: What the Evidence Says
The available human trial records point to a subcutaneous shot into the fatty layer beneath the skin. The pharmacy label and prescriber—not an online injection map—set the site for a specific MOTS-c preparation.
-
Compounded Tirzepatide Side Effects: What Changes?
Most side effects come from tirzepatide itself. Compounding can add a second layer of risk through concentration, measurement, added ingredients, sterility, and potency.
-
Tirzepatide for Seniors: What New 2026 Data Show
Age 65 alone does not rule out tirzepatide. New 2026 research is reassuring, but adults over 75 remain underrepresented and the safest decision turns on muscle reserve, hydration, kidney health and other medicines.
-
Semaglutide and Kidney Disease: The Full Picture
In the largest trial on the question, serious kidney events were 24% less common on semaglutide than on placebo. The other half of the story is dehydration — and the two keep getting confused.
-
Tirzepatide and Blood Pressure: Does It Lower It?
Yes—blood pressure often falls during tirzepatide treatment, mostly alongside weight loss. That can be welcome, but it also means people taking blood-pressure medicine may need closer review if lightheadedness starts.
-
Tirzepatide and Gallbladder Risk: Small but Real
Gallstones turn up in about 1 in 100 people on tirzepatide in the trials — barely above placebo — but inflamed gallbladders are three and a half times as common. Here is why, and the pain pattern that means call someone today.
-
How to Use PT-141: It's As-Needed, Not Daily
PT-141 is taken before anticipated activity rather than on a daily schedule. Here is what the approved label sets out, what a compounded vial changes, and what the prescriber decides.
-
Kisspeptin for Women: What the Research Shows
Kisspeptin has been given to women in a handful of small hospital trials — to mature eggs during IVF, to restart stalled hormone signalling, and once to watch the brain respond to sexual cues. Here is what those studies found, and what they did not.
-
How to Report Peptide Side Effects So It Counts
An NBC News investigation in August found that problems linked to peptides often go nowhere at all. Here is where a report actually lands, and in what order to make it.
-
Semaglutide and Vision: What's Real, What's Rare
Most people never have an eye problem because of semaglutide. Two things do come up, though, and they get mixed together constantly — so here is what each one actually is.
Page 1 of 3 · 56 articles